Market news
CHICAGO and FORT WORTH, Texas, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers, today announced that it will present at the H.C. Wainwright 28th Annual Global Investment Conference taking place September 14-16, 2026, in New York City. In addition, the management team will be available for one-on-one mee
Actuate Therapeutics, Inc. (ACTU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Gainers NextCure (NASDAQ:NXTC) stock increased by 201.4% to $6.57 during Tuesday's regular session. The market value of their outstanding shares is at $7.8 million. Shuttle Pharmaceuticals (NASDAQ:SHPH) shares
Gainers Agenus (NASDAQ:AGEN) shares increased by 95.8% to $6.56 during Monday's regular session. The market value of their outstanding shares is at $139.5 million. Q32 Bio (NASDAQ:QTTB) stock rose 81.08% to $20.3.
This is the newest page. Registered accounts read further back.